Needham Trims COR to 'Buy'

But analyst Mark Monane thinks the firm's fundamentals are quite strong

Needham downgraded COR Therapeutics (CORR ) to buy from strong buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.